These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 6152369)

  • 1. Inhibition of hepatic drug metabolism by (+)-cyanidanol-3 (Catergen) in chronic alcoholic liver disease.
    Pár A; Horváth T; Beró T; Kádas I; Pakodi F; Jávor T
    Acta Physiol Hung; 1984; 64(3-4):449-54. PubMed ID: 6152369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect of (+)-cyanidanol-3 in toxic alcoholic liver disease and in chronic active hepatitis.
    Abonyi M; Kisfaludy S; Szalay F
    Acta Physiol Hung; 1984; 64(3-4):455-60. PubMed ID: 6397971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, enzymological and histological changes in chronic diffuse liver diseases following (+)-cyanidanol-3 (Catergen) treatment.
    Halmy L; Dávid K; Nagy I; Stotz G; Kelemen JT
    Acta Physiol Hung; 1984; 64(3-4):461-70. PubMed ID: 6152370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between biochemical tests, parameters of drug elimination and hepatic enzyme induction in chronic liver diseases.
    Horváth T; Pár A; Beró T; Kádas I; Fábián C; Jávor T
    Acta Med Hung; 1983; 40(4):203-13. PubMed ID: 6674914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug metabolism in alcoholic liver disease.
    Horváth T; Pár A; Past T; Tapsonyi Z; Ruzsa C; Kádas I; Jávor T
    Acta Med Acad Sci Hung; 1982; 39(3-4):169-77. PubMed ID: 7185242
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of (+)-cyanidanol-3 (Catergen) in chronic active hepatitis. (Catergen plus prednisolone versus prednisolone in a controlled study).
    Pár A; Paál M; Kádas I; Kerekes E; Jávor T
    Acta Med Hung; 1983; 40(1):17-24. PubMed ID: 6664741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of chronic diseases of the liver with catergen].
    Loginov AS; Dzhalalov KD; Blok IuE; Bendikov EA; Ausheva LKh
    Ter Arkh; 1986; 58(2):73-6. PubMed ID: 3704945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of (+)-cyanidanol-3 on chronic liver injury.
    Kovách G; Salamon F
    Acta Physiol Hung; 1984; 64(3-4):443-8. PubMed ID: 6152368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disorders of biotransformation during the progression of alcoholic liver disease.
    Horváth T; Pár A; Past T; Beró T; Tapsonyi Z; Kádas I
    Acta Med Hung; 1986; 43(4):351-7. PubMed ID: 3601579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of biotransformation capacity in patients with chronic liver diseases by pharmacokinetic methods: experimental trials.
    Horváth T; Past T; Tatai Z; Pár A; Kádas I; Tapsonyi Z; Jávor T
    Pol J Pharmacol Pharm; 1984; 36(4):361-71. PubMed ID: 6396596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A new therapy of hepatic insufficiency. Experiments with (+)-3--cyanidanol. Its importance in the treatment of alcoholic hepatitis].
    Traissac FJ; Borg R
    Minerva Dietol Gastroenterol; 1977; 23(3):237-42. PubMed ID: 372845
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of chronic hepatitis. A comparative study of the effect azathioprine and (+)-cyanidanol-3].
    Aguilar Reina J; de la Santa López J; Cuadras Avellana CM; Kern A
    Fortschr Med; 1978 Jan; 96(2):75-9. PubMed ID: 74352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influence of (+)-cyanidanol-3 on the course of acute viral hepatitis (author's transl)].
    Vido I; Schmidt FW; Müller R; Ranft U; Wildhirt E; Holzer E; Wallnöfer H; Korb G
    Dtsch Med Wochenschr; 1980 Mar; 105(10):330-2. PubMed ID: 6153953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-adrenoceptor blocking drugs and cytochrome P-450: the influence of propranolol treatment on caffeine, antipyrine, D-glucaric acid and indocyanine green elimination in patients with hepatic disorders.
    Traeger A; Horváth T; Rechenbach C; Jávor T
    Int J Clin Pharmacol Res; 1986; 6(3):235-9. PubMed ID: 3744626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human tolerance of flumecinol (Zixoryn, RGH-3332), its regime and dosage in healthy volunteers.
    Vezekenyi Z; Ferenci J; Radnai B; Horvath T; Past T; Nagy L; Jávor T
    Int J Clin Pharmacol Res; 1983; 3(2):77-88. PubMed ID: 6679516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of alphamethyldopa on the half-lives of antipyrine, tolbutamide and D-glucaric acid excretion in man.
    Gachályi B; Tornyossy M; Vas A; Káldor A
    Int J Clin Pharmacol Ther Toxicol; 1980 Mar; 18(3):133-5. PubMed ID: 6103880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A contribution as to the effect of (+)-Cyanidanol-3 in chronic liver disease (author's transl)].
    Sondern W; Leube G
    Med Klin; 1978 Oct; 73(41):1432-6. PubMed ID: 703670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (+)-Cyanidanol-3 for alcoholic liver disease: results of a six-month clinical trial.
    World MJ; Aps EJ; Shaw GK; Thomson AD
    Alcohol Alcohol; 1984; 19(1):23-9. PubMed ID: 6149758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cyanidanol-3 on lysosomal enzyme activity of serum and granulocytes in chronic liver disease and active hepatitis.
    Fehér J; Toncsev H; Sréter L; Cornides A; Kiss A
    Int J Tissue React; 1984; 6(1):75-80. PubMed ID: 6715121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of phenobarbital on unconjugated bilirubin clearance, gamma-glutamyltranspeptidase and urinary d-glucaric acid in patients with Gilbert's syndrome.
    Kawasaki H; Murawaki Y; Kimura N; Hirayama C
    Hepatogastroenterology; 1982 Dec; 29(6):252-5. PubMed ID: 6130037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.